Khavinson short peptides (Pinealon, Cortagen, Vesugen, Bonothyrk, Cardiogen, others)
Family of two-to-four amino-acid peptides developed by the Khavinson group as proposed tissue-specific bioregulators.
At a glance
What it is: Family of two-to-four amino-acid peptides developed by the Khavinson group as proposed tissue-specific bioregulators..
Primary research applications:
- Tissue-specific regenerative research (Khavinson framework)
- Longevity and healthspan research interest
Editorial summary: The Khavinson short peptides are a family of small (typically 2–4 amino acid) peptides developed in Russia under the framework of "tissue-specific bioregulators." The literature is concentrated heavily in one research lineage and has limited independent replication or peer-reviewed clinical trials in mainstream Western journals. They remain culturally significant in the longevity discourse but should be evaluated with that provenance in mind.
- Class / structure
- Short peptides (2–4 amino acids) — e.g., Pinealon (Glu-Asp-Arg), Cortagen (Ala-Glu-Asp-Pro), Vesugen (Lys-Glu-Asp)
- Half-life
- Very short systemic half-life
- First described
- 1970s onward (Khavinson group)
- Regulatory status
- Sold as supplements / dietary peptides in Russia and elsewhere; not FDA-approved as drugs
What is Khavinson short peptides?
The Khavinson short peptides are a research-and-supplement category, not a single drug. The most commonly discussed include Pinealon (claimed cognitive support), Cortagen (claimed cortex/healing), Vesugen (claimed vascular), Bonothyrk (claimed thyroid), and Cardiogen (claimed cardiac).
Discovery and development
Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology have, over several decades, published extensively on a family of short peptides proposed as "tissue-specific bioregulators" — meaning each peptide is claimed to selectively support function in a particular organ system (pineal, thymus, vascular, cardiac, etc.). The concept extends an older Russian school of "peptide bioregulators" originating with cytomedins and cytogens.
Mechanism of action
The Khavinson framework proposes that these short peptides reach the cell nucleus and interact directly with specific DNA sequences to modulate gene expression in tissue-selective ways. Outside the originating group, this mechanism remains controversial — the proposed direct DNA interactions of small peptides are not well established in the broader peer-reviewed literature.[1]
Pharmacokinetics
The very short systemic half-life of these tiny peptides is one of the open scientific questions about how meaningful systemic effects could be sustained from typical doses. Proposed mechanisms include direct epigenetic interactions with DNA — claims that remain controversial outside the originating group.
What the research shows
The peer-reviewed literature on Khavinson short peptides is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Tissue-specific bioregulators reach the nucleus and modulate gene expression | Originating-group framework; not widely established | Uncertain |
| Reduces mortality in elderly cohorts with cyclic administration | Published by originating group; not independently replicated | Uncertain |
| Should be evaluated as established longevity therapeutics | Not on current Western evidence base | Unsupported |
Reported user experiences
How the research describes administration
Most Khavinson peptides are administered as oral capsules in supplement form; some are given as nasal sprays. Original research used parenteral routes in some studies.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
The Khavinson short peptides represent a culturally significant strand of longevity discourse with a real research history, but a research history that has not yet been broadly validated by independent groups. For curious readers, the appropriate framing is intellectual interest — particularly around the underlying "tissue-specific bioregulator" concept — combined with explicit acknowledgement that the evidence base does not yet support confident efficacy claims at Western clinical-evidence standards.
Frequently asked questions
What is the difference between Pinealon, Cortagen, and the other Khavinson peptides?
Each is a different short peptide claimed to support a different tissue: Pinealon → pineal/cognitive, Cortagen → cortex/healing, Vesugen → vascular, Bonothyrk → thyroid, Cardiogen → cardiac, and so on.
Are Khavinson peptides FDA-approved?
No. They are sold internationally as supplements rather than as approved drugs.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. Pinealon application in elderly patients. Adv Gerontol. 2017;30(2):246-255. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+peptides